Yttrium-90 internal radiation therapy for hepatic malignancy

Surgical Oncology
Sean Garrean, N Joseph Espat

Abstract

Surgical resection is the only potentially curative strategy in the treatment of patients with hepatic malignancy. Unfortunately, due to advanced stage, underlying liver disease, or medical comorbidities, most patients are inoperable at the time of presentation. As a result, various locoregional therapies have emerged for otherwise unresectable hepatic tumors. One such modality is Yttrium-90 (Y(90)) internal radiation therapy. Numerous studies demonstrate the safety and potential survival benefit of intra-arterial Y(90) for primary and metastatic liver tumors. However, more data is needed in order to understand the exact role of Y(90) in the algorithm of hepatic tumor management. This review presents the available literature on Y(90) with the aim of defining the current status of Y(90) in the armamentarium of therapeutic strategies for hepatic malignancy.

References

Sep 1, 1979·Diseases of the Colon and Rectum·E D Grady
Oct 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J H AndersonC S McArdle
Jul 1, 1991·International Journal of Radiation Oncology, Biology, Physics·R A FoxB N Gray
Mar 1, 1982·Radiology·R V MantravadiE L Felix
Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·T S LawrenceL F Fajardo
Mar 14, 1996·The New England Journal of Medicine·V MazzaferroL Gennari
Apr 14, 1999·The British Journal of Surgery·J HeisterkampJ N Ijzermans
Jun 11, 1999·Annals of Surgery·Y FongL H Blumgart
May 25, 2002·European Journal of Nuclear Medicine and Molecular Imaging·Ching-yee Oliver WongHoward J Dworkin
Nov 27, 2002·Journal of Clinical Gastroenterology·Charles ChaLeslie H Blumgart
Jul 27, 2004·Annals of Surgery·Wan-yee LauThomas W T Leung
Dec 14, 2004·International Journal of Radiation Oncology, Biology, Physics·Andrew S KennedyCinthia Drachenberg
Feb 17, 2005·Journal of Vascular and Interventional Radiology : JVIR·James E GoinKenneth Thurston
May 5, 2005·Cancer Biotherapy & Radiopharmaceuticals·Gabriele PöpperlKlaus Tatsch
Aug 18, 2005·Journal of Vascular and Interventional Radiology : JVIR·Thomas K RheeRiad Salem
Mar 12, 2008·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·R S Stubbs, S K Wickremesekera

❮ Previous
Next ❯

Citations

Mar 12, 2008·European Journal of Nuclear Medicine and Molecular Imaging·M A D VenteA D van het Schip
Jul 12, 2008·European Journal of Nuclear Medicine and Molecular Imaging·Marta CremonesiGiovanni Paganelli
Feb 8, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Daniel Crístian Ferreira SoaresGilson Andrade Ramaldes
Oct 4, 2007·Journal of Vascular and Interventional Radiology : JVIR·Lourens Bester, Riad Salem
Jun 15, 2007·American Journal of Surgery·Sean GarreanN Joseph Espat
Sep 14, 2007·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Niraj J GusaniT Clark Gamblin
May 26, 2017·Journal of Surgical Oncology·Jeffrey Reha, Steven C Katz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.